Abstract

Hyperoxia contributes to the pathogenesis of bronchopulmonary dysplasia (BPD), a chronic lung disease of infants that is characterized by interrupted alveologenesis. Disrupted angiogenesis inhibits alveologenesis, but the mechanisms of disrupted angiogenesis in the developing lungs are poorly understood. In pre-clinical BPD models, hyperoxia increases the expression of extracellular signal-regulated kinases (ERK) 1/2; however, its effects on the lung endothelial ERK1/2 signaling are unclear. Further, whether ERK1/2 activation promotes lung angiogenesis in infants is unknown. Hence, we tested the following hypotheses: (1) hyperoxia exposure will increase lung endothelial ERK1/2 signaling in neonatal C57BL/6J (WT) mice and in fetal human pulmonary artery endothelial cells (HPAECs); (2) ERK1/2 inhibition will disrupt angiogenesis in vitro by repressing cell cycle progression. In mice, hyperoxia exposure transiently increased lung endothelial ERK1/2 activation at one week of life, before inhibiting it at two weeks of life. Interestingly, hyperoxia-mediated decrease in ERK1/2 activation in mice was associated with decreased angiogenesis and increased endothelial cell apoptosis. Hyperoxia also transiently activated ERK1/2 in HPAECs. ERK1/2 inhibition disrupted angiogenesis in vitro, and these effects were associated with altered levels of proteins that modulate cell cycle progression. Collectively, these findings support our hypotheses, emphasizing that the ERK1/2 pathway is a potential therapeutic target for BPD infants with decreased lung vascularization.

Highlights

  • Bronchopulmonary dysplasia (BPD) is a chronic lung disease of premature infants that is characterized by interrupted lung development [1]

  • We investigated the interaction between hyperoxia and ERK1/2 activation in mouse lungs and fetal human pulmonary artery endothelial cells (HPAECs)

  • We showed in the same model that exposure of mice to neonatal hyperoxia causes lung developmental abnormalities that persist into adolescence [30]

Read more

Summary

Introduction

Bronchopulmonary dysplasia (BPD) is a chronic lung disease of premature infants that is characterized by interrupted lung development [1]. Understanding the mechanisms that promote the development and function of the lung blood vessels is vital to prevent and treat this human disease. Toward this end, vascular endothelial growth factor (VEGF) and nitric oxide (NO) signaling pathways have been extensively investigated and have been shown to be necessary for lung development in health and disease in neonatal animals [7,8,9,10,11]. VEGF restores the alveolar and pulmonary vascular structure and function via the endothelial nitric oxide synthase pathway in experimental BPD and pulmonary hypertension (PH) [12,13,14]. There is a need to identify additional druggable molecular targets that can complement the inhaled NO therapy to promote the development and function of the lung vascular system

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call